复方苦参注射液与放疗和FP方案联用治疗中晚期中上段食道癌

目的：观察复方苦参注射液＋放疗＋FP化疗方案联用治疗中晚期中上段食道癌的临床疗效和药物毒副作用，并与放疗＋FP方案进行比较。方法：将74名中上段中晚期食道癌患者随机分为对照组和试验组各37名，两组均采用放疗加FP化疗：放疗总量为60～70Gy（6～7周）；每周行FP方案（PDD30mg，5-FU500mg）静脉增敏化疗1次，试验组在此基础上静脉注射复方苦参注射液30mL（d1-d3）。结果：试验组的近期有效率为91．89％，而对照组为64．68％，两组有显著差异（P〈0．05）；试验组病人的肿瘤放化疗毒副作用明显减轻，其3年生存率为56．75％，而对照组仅为32．42％，两组亦有显著差异（P〈0．05）。结论：中上段中晚期食道癌放疗加每周1次FP方案静脉增敏化疗，再静脉给予复方苦参注射液30mL，连用3天可提高中上段中晚期食道癌的近期有效率和远期生存率，减轻放化疗药物的毒副作用，为中上段中晚期食道癌患者提供了较为理想的治疗手段。

Combined Treatment with Compound Matrine Injection,Radiotherapy and FP Regimen for Advanced Esophageal Carcinoma of Upper and Middle Defects

Objective： To observe the clinical effect and drug side-effects of combined compound matrine injection, radiotherapy and FP regimen for treating advanced esophageal treatment of carcinoma of upper and middle defects, and to compare them with those of the therapeutics of radiotherapy and FP regi- men. Methods： 74 cases of the mentioned patients were divided into control group and test group random ly. Both of the two groups were given radiotherapy treatment. The total radio amount was 60-70 Gy/6-7 weeks, and both groups received intravenous FP regimen of PDD 30 mg （dl）, 5-Fu 500 mg（dl） once a week. Besides these, the test group received intravenous administration of compound matrine injection 30 mL （dl-d3）. Results： The short term effect of the testing group was 91.89% while that of the control group was 64.68%, the difference being significant （ P 〈0.05）. The toxic and side effects of radiotherapy and chemotherapy on the test group were reduced obviously. The 3-year survival rate of the test group was 56.75% and that of the control group is only 32.42%, the difference being significant （ P 〈 0.05）. Conclusion： The combined treatment of FP regimen and radiotherapy plus compound matrine injection （30 mL） can improve the short term effect and the long term survival rate of the patients with the advanced esophageal carcinoma of the upper and middle defects, without adverse effects. It is an ideal regimen to the above mentioned disease.